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Purpose. In low-income countries, prolactinomas are difficult to manage with dopamine agonists (DA). We compared the
effectiveness of DA inmicroprolactinomas as a first line treatment and as adjuvant therapy for residual macroprolactinomas treated
surgically. Methods. Our retrospective study analyzed 78 patients, 38 with microprolactinomas and 40 with macroprolactinomas.
Microprolactinomas were treated with DA. Macroprolactinomas were treated with microsurgical or endoscopic adenomectomies
and adjuvant DA. Surgical remission was defined as normoprolactinemia three months postoperatively, and long-term remission
as normoprolactinemia at the last control. Results. Surgical remission was achieved in 9 patients (23%). Postsurgical tumor mass
was reduced by 50% (34–68). Residual macroprolactinoma size was greater thanmicroprolactinoma size prior to treatment (10mm
versus 4mm, 𝑃 < 0.001). Both groups received similar doses of DA. Long-term remission occurred in 68% of microprolactinomas
and 43% of macroprolactinomas (𝑃 = 0.102). Prolactin (PRL) levels at the last control were similar in both groups (23.1 versus
32.9mcg/L, 𝑃 = 0.347). Conclusion. Comparable remission rates and PRL levels were reached in microprolactinomas and
macroprolactinomas using similar doses of DA. Although complete tumor resection is the goal of surgery, our study suggests that
even partial surgical removal has a role in treatment of prolactinomas since it may enhance the response to DA.
1. Introduction
Prolactinomas represent 40% of all pituitary tumors. They
are classified according to their size as macroprolactinomas
(>10mm) or microprolactinomas (<10mm). Treatment is
recommended when they are large enough to cause neu-
rologic symptoms and when hyperprolactinemia leads to
hypogonadism or galactorrhea [1]. The endocrine clinical
practice guidelines recommend the use of dopamine agonists
(DA) for the treatment of all symptomatic macro- and
microprolactinomas [2]. The two most commonly used DA
are bromocriptine and cabergoline. Cabergoline is more
expensive but is more effective in normalizing prolactin
(PRL) levels and in reducing tumor size. In addition, caber-
goline has fewer side effects [1, 3]. Surgery is recommended in
select cases when patients do not respond or are intolerant to
medical therapy, severe compressive symptoms exist, cystic
changes are present, or pituitary apoplexy occurs [1, 4].
However, pituitary surgery has been used as a first line
treatment in patients that favored surgery over dopamine
agonists with excellent results [5]. Larger tumors generally
require higher doses of dopamine agonists [6, 7] and aremore
resistant to treatment [8]. In low income countries such as
Croatia, the treatment of macroprolactinomas with medical
management alone proves to be challenging. High doses of
bromocriptine can lead to intolerable side effects such as
nausea, postural hypotension, and dizziness [3]. Moreover,
cabergoline is not registered in our country for this use, and
the costs are covered from our department’s annual budget.
Some patients require life-long therapy and these costs are
unsustainable [6]. In order to overcome this therapeutic
challenge, patients harboring macroprolactinomas are first
treated surgically. If additional medical therapy is required,
lower doses of bromocriptine or cabergoline are used. Stud-
ies have indicated that partial surgical removal of growth
hormone-secreting pituitary tumors enhances the response
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Table 1: Characteristics of men and women with micro- and macroprolactinomas at diagnosis.
Total Microprolactinomas Macroprolactinomas 𝑃
Number (%) 78 (100) 38 (54.3) 40 (45.7) NA
Pretreatment size (mm) 6.5 (4.0–18.0) 4.0 (3.0–6.0) 26.0 (16.3–31.8) <0.001
Men number (%) 23 (100) 0 (0) 23 (100) NA
Women number (%) 55 (100) 38 (69.1) 17 (30.9) NA
Age (years) 40.0 (32.0–53.0) 36.5 (32.000–50.0) 43.0 (32.0–62.0) 0.259
Serum prolactin levels (mcg/L) 113.6 (60.5–941.5) 63.5 (48.3–93.0) 995.5 (417.0–2500.0) <0.001
NA: not analyzed.
to somatostatin analogs in acromegaly [9, 10]. Likewise,
debulking of prolactinomas may also increase the efficacy of
dopamine agonists. This could potentially reduce the costs
of treatment because lower doses of cabergoline could be
used in patients with larger prolactinomas. Our hospital is the
reference center for pituitary surgery and has been involved
in pituitary microsurgery since 1986 and endoscopic surgery
since 2006. We currently have two dedicated neurosurgeons
who perform a minimal of 80 operations each per year with
excellent results. The aim of this study was to compare the
effectiveness of dopamine agonists in patients withmicropro-
lactinomas as a first line treatment and as adjuvant therapy for
patients with residual macroprolactinomas.
2. Patients and Methods
We searched for patients with prolactinomas in our elec-
tronic database from January 1, 2010, to December 31, 2013.
Microprolactinomas were defined as pituitary adenomas
<10mm in diameter with increased prolactin levels. Macro-
prolactinomaswere defined as pituitary adenomas>10mm in
diameter along with serum prolactin levels above 100mcg/L.
Only newly diagnosed patients were included in the study.
Exclusion criteria included patients who were treated with
dopamine agonists prior to surgery. All patients with micro-
prolactinomas were treated with DA. Patients with macro-
prolactinomas underwent microsurgical or endoscopic ade-
nomectomies. Two skilled neurosurgeons (each performs
>80 pituitary surgeries/year) operated on the patients using
microsurgical or endoscopic techniques. Bromocriptine was
given to patients with microprolactinomas and gradually
increased to 2.5mg/day taken as a single dose. Subsequent
doses were adjusted according to PRL levels and drug toler-
ance. Doses were increased by 2.5mg every 3 months when
needed. If patients could not tolerate bromocriptine, cabergo-
line was substituted. Cabergoline was introduced at a starting
dose of 0.5mg/week and then increased by 0.5mg increments
every 3 months depending on PRL levels. DA were initiated
in similar fashion in patients with macroprolactinomas who
did not meet the criteria for surgical remission. Surgical
remission was defined as normal PRL levels three months
postoperatively. Long-term remission was defined as normal
PRL levels at the last control visit. PRL was quantita-
tively measured using the DELFIA fluorescent method by
the PerkinElmer company (normal range for women: 2.0–
30.0 𝜇g/L and for men: 2.0–20.0 𝜇g/L). We used a 1.5-Tesla
MRI according to the standard protocol. It included native
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Figure 1: Flow of patients through the study.
T1- and T2-weighted imaging and dynamic T1-weighted
imaging after gadolinium-base contrast medium.The longest
diameter of the tumor mass was used to measure tumor size.
All human and animal rightswere respected during our study.
The ethics committee at our institution approved this study.
2.1. Statistical Analyses. Patients’ characteristics were
assessed with descriptive statistics presented as mean and
standard deviation ormedian with interquartile range values.
Due to relatively small patient groups, independent variables
were compared using Mann-Whitney test and Fisher’s exact
test accordingly. Changes in serumPRL levels were compared
using Wilcoxon’s test. Statistical analyses were performed
using SAS for Windows software, version 9.1.3. (SAS Inc.,
Cary, NC, USA) licensed to the Zagreb University School of
Medicine. 𝑃 value <0.05 was considered significant.
3. Results
We identified 102 patients with prolactinomas in our
database, 59 microprolactinomas and 43 macroprolactino-
mas (Figure 1). Twenty-one patients with microprolactino-
mas were excluded from the study, 18 were previously treated
with DA, and pituitary surgery was performed as first line
treatment in 3 patients.Three patients withmacroprolactino-
mas were previously treated withDA andwere excluded from
the study. There were 78 eligible patients with prolactinomas
(55 women and 23 men); 38 had microprolactinomas with a
median size of 4.0mm (range 3.0–6.0), and 40 hadmacropro-
lactinomas with a preoperative median size of 26mm (range
16.3–31.8). Patient and tumor characteristics are shown in
Table 1. Surgical remission was achieved in 9 patients (23%).
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Table 2: Treatment details for microprolactinomas treated with dopamine agonists and macroprolactinomas treated with adjuvant medical
therapy following surgery. Remission and relapse rates are presented in the two groups.
Microprolactinomas Macroprolactinomas 𝑃
Bromocriptine
dose (mg)
24/38
2.5 (2.5–5.0)
13/23
2.5 (2.5–5.0)
0.596
0.853
Cabergoline
dose (mg)
14/38
0.5 (0.5–0.69)
10/23
0.5 (0.5–1.0)
0.596
0.123
Surgical remission — 23% (9/40)
Duration of treatment (months) 25.0 (15.0–87.0) 25.5 (10.0–43.0) 0.404
Long-term remission 68% (26/38) 43% (10/23) 0.122
PRL at the last control 23.1 (12.4–35.8) 32.9 (12.0–70.0) 0.279
Withdrawal of therapy 16/38 3/23 0.022
Normal PRL after withdrawal 15.8% (6/38) 0% (0/3) 0.073
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Figure 2: PRL levels at baseline and at the last control visit in patients with microprolactinomas (a) and macroprolactinomas (b).
Complications occurred in three patients (8%): one patient
had cerebrospinal fluid leakage, one had nasal bleeding,
and one had transient diabetes insipidus. Tumor mass was
reduced by a median of 50% (range 34–68) in patients with
residual tumors. Patients with residual macroprolactinoma
had significantly larger tumor masses than microprolactino-
mas (10mm versus 4mm, 𝑃 < 0.001). In the macropro-
lactinoma group, PRL levels three months postoperatively
were similar to the initial PRL levels of microprolactinomas
(83.3mcg/L (50.0–157.6) versus 63.5 (48.3–93.0), 𝑃 = 0.275).
DA were given to 23 patients with residual macroprolacti-
nomas that did not have surgical remission. Thirty-seven
percent of patients with microprolactinomas were intolerant
to bromocriptine and were switched to cabergoline. Fol-
lowing surgery, 43% of patients with macroprolactinomas
were switched to cabergoline due to intolerance. The dose of
cabergoline was similar in patients with microprolactinomas
(0.5mg; range 0.50–0.69) and macroprolactinomas (0.5mg;
range 0.5–1.0), 𝑃 = 0.123. Both groups received 2.5mg
(range 2.5–5.0) of bromocriptine (𝑃 = 0.853). Patients with
microprolactinomas were treated with DA for a median of
25.0 months (range 15.0–87.0) and patients with residual
macroprolactinomas were treated with DA for a median of
25.5 months (range 10.0–43.0), 𝑃 = 0.404. After a median
of 25.5 months, PRL levels decreased significantly in both
groups (Table 2). Long-term remission was achieved in 68%
of patients withmicroprolactinomas and 43%of patients with
macroprolactinomas (𝑃 = 0.102). There was no statistically
significant difference in terms of remission or PRL levels at
the end of treatment (Figure 2). DA were discontinued in
42% (16/38) of patients with microprolactinomas and 62.5%
(10/16) of these patients had relapses. Only three patients
with macroprolactinomas were discontinued from medical
therapy and all had relapses. Two patients with surgical
remission had tumor recurrence over a 24-month period.
4. Discussion
Dopamine agonists are recommended as first line therapy in
all symptomatic micro- and macroprolactinomas. However,
in low-income countries, macroprolactinomas are difficult to
manage with dopamine agonists alone due to the costs and
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side-effect profile of these drugs [1, 11]. Study by Verhelst et al.
showed that patients with macroprolactinomas need higher
median cabergoline dose to achieve normoprolactinemia,
compared with those with idiopathic hyperprolactinemia or
a microprolactinoma (1.0mg/week versus 0.5mg/week) [6].
Moreover, there is a dose-dependent suppression of serum
prolactin by cabergoline in patients with prolactinomas [7].
Given the fact that macroprolactinomas tend to have higher
prolactin levels, it is reasonable that macroprolactinomas
require higher doses of DA. Similar studies regarding the
dose effects of bromocriptine are lacking. However, similar
remission rateswere observed in patientswithmacroprolacti-
nomas treated with 10–20mg of bromocriptine and patients
with microprolactinomas treated with 2.5–10mg daily [11,
12], suggesting that macroprolactinomas generally require
higher doses of bromocriptine. High dose bromocriptine is
associated with intolerable side effects. Cabergoline is on the
other hand better tolerated, but it is more expensive and
most patients require life-long therapy [11]. Recommended
doses of DA are 2.5mg of bromocriptine twice daily and
0.5mg of cabergoline twice weekly [1, 3]. In a randomized
trial comparing cabergoline and bromocriptine, normopro-
lactinemia was achieved in 83% of patients treated with
cabergoline and 59% of patients treated with bromocriptine
[3]. With these optimal doses, studies have shown that, after
cessation of medication, recurrences can range from 36 to
80% [13, 14]. In addition, higher recurrences are seen with
larger tumors andwith higher PRL levels at diagnosis [2].One
meta-analysis showed that remission after drug withdrawal
was 21% for patients with microprolactinomas and 16% for
patients with macroprolactinomas [15]. In our study, patients
with microprolactinomas and residual macroprolactinomas
were treated with similar doses of DA and had the same
PRL measurements after 2 years of treatment (Figure 2). Our
patients did not receive the recommended doses of dopamine
agonists because high doses of bromocriptinewere associated
with intolerable side effects and we could not afford to
give cabergoline at higher doses due to financial reasons.
This could explain why our results are inferior to similar
studies. Nevertheless, 68% of patients with microprolactino-
mas and 43% of patients with macroprolactinomas reached
normoprolactinemia. Although surgery is recommended in
select cases, it should be considered as an alternative to
medical therapy when the costs of dopamine agonists limit
their use. When surgery is performed in specialized centers,
normoprolactinemia is reached in 67–88% of cases. These
results are comparable to remission rates with dopamine
agonists [4]. However, similar toDAwithdrawal, studies have
shown that 7–50% of prolactinomas that are treated surgically
recur. Risks of pituitary surgery include hypopituitarism,
diabetes insipidus, cerebrospinal fluid leaks, and infection [2].
Several studies have demonstrated that fewer complications
are present when a more experienced pituitary surgeon
performs the procedures [14]. Therefore, when surgery is
considered, an experienced surgeon must be present. Due to
the risks associated with these procedures, we recommend
pituitary surgery as a valuable treatment option for patients
with macroprolactinomas. Even partial resection has a role
in treatment of prolactinomas since it may enhance the
response to dopamine agonists. Microprolactinomas are well
controlledwith lower doses ofDA, and these patientsmay not
be subjected to the risks of surgery.
5. Conclusion
Pituitary surgery may be a valuable first line treatment of
macroprolactinomas. Comparable remission rates and pro-
lactin levelswere reached inmicroprolactinomas and residual
macroprolactinomas using similar doses of dopamine ago-
nists. Although the complete resection of the tumor mass
is the goal of surgery, our study suggests that even partial
surgical removal has a role in treatment of prolactinomas
since it may enhance the response to dopamine agonists.
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